Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Kisunla is a prescription amyloid beta-directed antibody containing donanemab-azbt. It is indicated for Alzheimer disease, with treatment started in patients at the mild cognitive impairment or mild dementia stage. Amyloid beta pathology is confirmed before treatment begins.
read more about kisunla ...Donanemab-azbt is a monoclonal antibody directed against insoluble N-truncated pyroglutamate amyloid beta. It binds this form of amyloid beta and reduces amyloid plaque levels in the brain.
Kisunla is used in patients with Alzheimer disease at the mild cognitive impairment or mild dementia stage after amyloid beta pathology has been confirmed. Apolipoprotein E epsilon 4 testing is performed before treatment to inform the risk of amyloid-related imaging abnormalities.
Kisunla is infused intravenously over about 30 minutes every four weeks. The first infusion is 350 mg, the second is 700 mg, the third is 1050 mg, and the fourth and later infusions are 1400 mg. Treatment discontinuation can be considered after amyloid plaques fall to minimal levels on amyloid PET imaging.
Kisunla carries a boxed warning for amyloid-related imaging abnormalities, including edema and hemosiderin deposition. Serious and fatal events can occur, including intracerebral hemorrhage. A brain MRI is obtained before treatment and before the second, third, fourth, and seventh infusions. Infusion-related reactions can also occur.
Kisunla treats Alzheimer disease and is started at the mild cognitive impairment or mild dementia stage.
The first four monthly doses are 350 mg, 700 mg, 1050 mg, and 1400 mg, with 1400 mg every four weeks thereafter.
Brain MRI monitoring is used to detect amyloid-related imaging abnormalities, which can include brain swelling or bleeding.
Yes. The boxed warning concerns amyloid-related imaging abnormalities, including potentially serious or fatal events.
DailyMed - KISUNLA (donanemab-azbt) injection, solution. https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=human&query=Donanemab. Date Accessed October 8, 2026.
Donanemab-azbt Injection. MedlinePlus. https://www.medlineplus.gov/druginfo/meds/a624048.html. Date Accessed October 8, 2026.
Donanemab. PubChem. https://pubchem.ncbi.nlm.nih.gov/substance/252166569. Date Accessed October 8, 2026.
KISUNLA (donanemab-azbt) Prescribing Information. Eli Lilly and Company. https://uspl.lilly.com/kisunla/kisunla.html?s=pi. Date Accessed October 8, 2026.
KISUNLA (donanemab-azbt) Prescribing Information. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761248s004lbl.pdf. Date Accessed October 8, 2026.